Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6 to 16 years old~* Physician-diagnosed asthma for at least one year~* At least one severe asthma exacerbation in the previous year~* Use of asthma medications (daily controller medication \[ICS or leukotriene inhibitor\] or inhaled β2-agonist \[at least three days per week\]) for at least six months in the previous year~* Vitamin D insufficiency (i.e., serum vitamin D (25(OH)D level \<30 ng/ml (75 nmol/L))~* FEV1 ≥70 % of predicted~* Positive bronchodilator response (i.e., increase in FEV1 ≥8% from baseline after inhaled short acting beta agonist or increased airway responsiveness to methacholine (PC20 ≤8 mg/ml if not on ICS or PC20 ≤16 mg/ml if on ICS)~* Study protocol (i.e., age-appropriate dose of Fluticasone and no other asthma controller medications) approved by the child's regular doctor~* Parental consent and child's assent to participate in the study.~Additional inclusion criteria applied after the run-in period, to be eligible for randomization:~* Adherence with ICS and study medication (≥75% use \[at least 21 of 28 days\]) during the run-in period~* Willingness to be randomized and complete study~Exclusion Criteria:~* Serum calcium \>10.8 mg/dl~* Serum 25(OH) D \<14 ng/ml (35 nmol/L)~* Chronic respiratory disorder other than asthma~* Severe asthma (intubation for asthma at any time OR ≥3 hospitalizations for asthma in previous year OR ≥6 severe asthma exacerbations in previous year)~* Hepatic/renal disease, rickets, malabsorption, or other diseases that would affect vitamin D metabolism~* Current smoking, or former smoking if ≥5 pack-years~* Immune deficiency, cleft palate or Down's syndrome~* Treatment with anticonvulsants or ≥1,000 IU/day of vitamin D2 or D3~* Chronic oral corticosteroid therapy~* Inability to perform acceptable spirometry~* Use of investigational therapies or participation in trials 30 days before or during the study~* Participant is currently breast feeding an infant~* Pregnancy~* Weight less than 10 kg~* Plans to move out of the study site area in the next year~Additional exclusion criteria applied after the run-in period:~* Any severe asthma exacerbation during the run-in period~* Need for asthma medications other than ICS and p.r.n. rescue inhalers during the run-in period

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- vitamin D3 (Type: EXPERIMENTAL): Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
- placebo (Type: PLACEBO_COMPARATOR): placebo formulations will be in gel cap form and identical to the active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).